XML 70 R59.htm IDEA: XBRL DOCUMENT v3.19.1
Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)
$ in Thousands
Feb. 18, 2019
Feb. 08, 2019
Jan. 23, 2019
Eyemax [Member] | Sean Brynjelsen [Member]      
Ownership interest percentage 33.00%    
Licensing and Supply Agreement [Member] | Upon Execution of the Agreement [Member]      
Payment of license     $ 350
Licensing and Supply Agreement [Member] | Upon Successful Bioequivalence Study [Member]      
Payment of license     350
Licensing and Supply Agreement [Member] | Upon NDA Acceptance [Member]      
Payment of license     325
Licensing and Supply Agreement [Member] | Upon NDA Approval [Member]      
Payment of license     325
Licensing and Supply Agreement [Member] | Upon Issuance of Patent [Member]      
Payment of license     650
Licensing and Supply Agreement [Member] | Product Sales [Member]      
Payment of license     500
Licensing and Supply Agreement [Member] | Maximum [Member] | Calendar Year [Member]      
Payment of license     $ 10,000
Exclusive Licensing and Supply Agreement - 202 [Member]      
Percentage for additional profit for commercial sale of product   50.00%  
Exclusive Licensing and Supply Agreement - 202 [Member] | Upon FDA Approval [Member]      
Payment of license   $ 750  
Exclusive Licensing and Supply Agreement - 203 [Member]      
Percentage for additional profit for commercial sale of product   50.00%  
Exclusive Licensing and Supply Agreement - 203 [Member] | Upon FDA Approval [Member]      
Payment of license   $ 750  
Amended and Restated Agreement [Member] | Maximum [Member]      
Royalties $ 2,000    
Liqmeds Worldwide Limited ("LMW") [Member]      
Percentage for product profit from commercial sales     35.00%
Agreement term     10 years
Liqmeds Worldwide Limited ("LMW") [Member] | Licensing and Supply Agreement [Member] | Maximum [Member]      
Payment of license     $ 2,500
Sintetica SA [Member] | Exclusive Licensing and Supply Agreement - 202 [Member]      
Payment of license   $ 2,000  
Percentage for marketing fees   5.00%  
Proceeds from license received   $ 500  
Percentage for additional profit for commercial sale of product   50.00%  
Agreement term for commercial sale of product   10 years  
Sintetica SA [Member] | Exclusive Licensing and Supply Agreement - 203 [Member]      
Payment of license   $ 1,000  
Percentage for marketing fees   5.00%  
Proceeds from license received   $ 500  
Percentage for additional profit for commercial sale of product   50.00%  
Agreement term for commercial sale of product   10 years  
Eyemax [Member] | Amended and Restated Agreement [Member]      
Description for milestone payment Pursuant to the Amended Agreement, the Company remain obligated to pay Eyemax two milestones: (i) one milestone payment for $250,000 upon regulatory approval in the territory by the FDA of the first single agent product and (ii) one milestone payment for $500,000 following the first commercial sale of the first single agent product in the territory.    
Eyemax [Member] | Amended and Restated Agreement [Member] | One Milestone [Member]      
Payment for milestone $ 250    
Eyemax [Member] | Amended and Restated Agreement [Member] | Two Milestone [Member]      
Payment for milestone 500    
Bausch Health Ireland Limited [Member] | Asset Purchase Agreement [Member]      
Payment for milestone 500    
Bausch Health Ireland Limited [Member] | Asset Purchase Agreement [Member] | Commercial Milestone [Member]      
Payment for milestone $ 2,500